$NBIO "There continue to be significant unmet medi

$NBIO "There continue to be significant unmet medical needs across a variety of cancers," remarked Sean Carrick, CEO of Nascent Biotech. "We are highly encouraged by Pritumumab's potential as an innovative, first-in-class treatment candidate, and we are delighted to be working closely with BioRay in this collaboration."

https://finance.yahoo.com/news/nascent-biotec...00418.html